MDSpire - Takeaway
From the Journals

VIS-101 Shows Activity in nAMD Study

Data from a phase 2a study in China suggest visual acuity gains and potential treatment durability

  • March 23, 2026

  • 2 min

Share

  • 1

    VIS-101 targets VEGF-A and angiopoietin-

  • 2

    Phase 2a study involved 38 patients aged 50-

  • 3

    Significant mean gains in visual acuity (ETDRS scale).

  • 4

    Reduction in retinal thickness by approx. 100-150 µm.

  • 5

    2/3 of patients did not need retreatment at 4 months.

  • 6

    Phase 2b study planned for

  • 7

    VIS-101 is also being tested in diabetic macular edema.

  • 8

    Investigational status under NovaBridge subsidiary Visara.

Original Source(s)

VIS-101 Shows Activity in nAMD Study

  • March 23, 2026

Related Content

Virtual Reality Tests Vision Therapy

Researchers evaluate immersive training for pediatric exotropia.

FDA Approves TECNIS PureSee IOL for Cataract Surgery

First FDA-approved extended depth of focus (EDOF) IOL maintaining contrast sensitivity comparable to an aspheric monofocal IOL

  • March 23, 2026

  • 2 min
The European Myopia Network

A collaborative platform for myopia experts in Europe